1. Home
  2. RH vs BEAM Comparison

RH vs BEAM Comparison

Compare RH & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RH

RH

RH

HOLD

Current Price

$129.57

Market Cap

2.8B

ML Signal

HOLD

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$30.83

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RH
BEAM
Founded
1979
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
3.0B
IPO Year
2011
2019

Fundamental Metrics

Financial Performance
Metric
RH
BEAM
Price
$129.57
$30.83
Analyst Decision
Hold
Buy
Analyst Count
14
12
Target Price
$167.00
$50.75
AVG Volume (30 Days)
1.0M
2.0M
Earning Date
06-11-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
74.31
82.31
EPS
6.31
N/A
Revenue
$1,193,046,000.00
$24,000.00
Revenue This Year
$8.39
N/A
Revenue Next Year
$9.44
$33.77
P/E Ratio
$20.90
N/A
Revenue Growth
24.52
33.33
52 Week Low
$106.30
$15.52
52 Week High
$256.78
$36.44

Technical Indicators

Market Signals
Indicator
RH
BEAM
Relative Strength Index (RSI) 44.45 59.15
Support Level $127.00 $22.24
Resistance Level $144.80 $32.01
Average True Range (ATR) 5.82 1.81
MACD 0.78 0.01
Stochastic Oscillator 17.15 71.15

Price Performance

Historical Comparison
RH
BEAM

About RH RH

RH is a luxury furniture and lifestyle retailer primarily operating in the $136 billion domestic furniture and home furnishing industry. The firm offers merchandise across many categories, including furniture, lighting, textiles, bath, decor, and is growing the presence of its hospitality business with 24 restaurant locations, including RH Guesthouse. RH innovates, curates, and integrates products, categories, services, and businesses across channels and brand extensions (RH Modern and Waterworks, for example). RH is fully integrated across channels and is positioned to broaden its addressable market over the next decade via expanding abroad, its World of RH digital platform (highlighting offerings outside of home furnishings), and offerings in architecture, media, and more.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.

Share on Social Networks: